• Roche diagnostics unit secured CE mark certification for its Elecsys pTau217 blood test as a rule-in or rule-out aid for amyloid pathology in Alzheimer’s diagnosis.
• Company plans to present new data on the test’s primary-care and secondary-care performance at AAIC 2026 in London on July 12-15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202607070100BIZWIRE_USPR_____20260706_BW139373) on July 07, 2026, and is solely responsible for the information contained therein.